Technology Changing Life^®

Oncolytics is a biotechnology company developing REOLYSIN^®, an immuno-oncology viral-agent, as a potential treatment for a variety of tumor types. Oncolytics’ clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in breast cancer.

Learn More About REOLYSIN^®